BeiGene, Ltd.

NASDAQ:

HK:

BGNE

6160

BeiGene's mission is to build the first next-generation biopharmaceutical company, one that expands the highest quality therapies to billions more people through courage, persistent innovation, and challenging the status quo.
BeiGene is passionate about its people, science, and creating a lasting impact. These priorities are of utmost importance to the organization. BeiGene strives to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity. As part of the global clinical development program, BeiGene is enrolling patients in 34 countries to participate in clinical trials.

Key Facts

Auditor

Public Listing

Domicile

HQ/Management

Location of Key Operations

IR Contact

Ernst & Young LLP

IPO (February 3, 2016)

Cayman Islands

Changping, Beijing, China

Craig West, Internal

857-302-5189

Analyst Coverage

Latest News